Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
OBJECTIVE:To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-naïve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate syntha...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4871516?pdf=render |
id |
doaj-6af2722cccc44c75865422849562ce5f |
---|---|
record_format |
Article |
spelling |
doaj-6af2722cccc44c75865422849562ce5f2020-11-24T21:47:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01115e015429310.1371/journal.pone.0154293Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.Andrés Felipe CardonaLeonardo RojasBeatriz WillsOscar ArrietaHernán CarranzaCarlos VargasJorge OteroMauricio CuelloLuis CorralesClaudio MartínCarlos OrtizSandra FrancoRafael RosellCLICaPOBJECTIVE:To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-naïve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. The primary endpoints were the overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). METHODS:A cohort of 144 patients were administered pemetrexed (500 mg/m2), carboplatin (AUC, 5.0 mg/ml/min) and bevacizumab (7.5 mg/kg) intravenously every three weeks for up to four cycles. Maintenance PB was administered until disease progression or unacceptable toxicity. RESULTS:One hundred forty-four Colombian patients with a median follow-up of 13.8 months and a median number of 6 maintenance cycles (range, 1-32) were assessed. The ORR among the patients was 66% (95% CI, 47% to 79%). The median PFS and (OS) rates were 7.9 months (95% CI, 5.9-10.0 months) and 21.4 months (95% CI, 18.3 to 24.4 months), respectively. We documented grade 3/4 hematologic toxicities, including anemia (14%), neutropenia (8%), and thrombocytopenia (16%). The identified grade 3/4 non-hematologic toxicities were proteinuria (2%), venous thrombosis (4%), fatigue (11%), infection (6%), nephrotoxicity (2%), and sensory neuropathy (4%). No grade >3 hemorrhagic events or hypertension cases were reported. OS was significantly higher in patients with the lowest TS mRNA levels [median, 29.6 months (95% CI, 26.2-32.9)] compared with those in patients with higher levels [median, 9.3 months (95% CI, 6.6-12.0); p = 0.0001]. TS expression (mRNA levels or protein expression) did not influence the treatment response. CONCLUSION:Overall, PCB followed by maintenance pemetrexed and bevacizumab was effective and tolerable in Hispanic patients with non-squamous NSCLC. This regimen was associated with acceptable toxicity and prolonged OS, particularly in patients with low TS expression. We found a role for Ki67 and TS expression as prognostic factors.http://europepmc.org/articles/PMC4871516?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Andrés Felipe Cardona Leonardo Rojas Beatriz Wills Oscar Arrieta Hernán Carranza Carlos Vargas Jorge Otero Mauricio Cuello Luis Corrales Claudio Martín Carlos Ortiz Sandra Franco Rafael Rosell CLICaP |
spellingShingle |
Andrés Felipe Cardona Leonardo Rojas Beatriz Wills Oscar Arrieta Hernán Carranza Carlos Vargas Jorge Otero Mauricio Cuello Luis Corrales Claudio Martín Carlos Ortiz Sandra Franco Rafael Rosell CLICaP Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression. PLoS ONE |
author_facet |
Andrés Felipe Cardona Leonardo Rojas Beatriz Wills Oscar Arrieta Hernán Carranza Carlos Vargas Jorge Otero Mauricio Cuello Luis Corrales Claudio Martín Carlos Ortiz Sandra Franco Rafael Rosell CLICaP |
author_sort |
Andrés Felipe Cardona |
title |
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression. |
title_short |
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression. |
title_full |
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression. |
title_fullStr |
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression. |
title_full_unstemmed |
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression. |
title_sort |
pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab in hispanic patients with non-squamous non-small cell lung cancer: outcomes according to thymidylate synthase expression. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
OBJECTIVE:To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-naïve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. The primary endpoints were the overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). METHODS:A cohort of 144 patients were administered pemetrexed (500 mg/m2), carboplatin (AUC, 5.0 mg/ml/min) and bevacizumab (7.5 mg/kg) intravenously every three weeks for up to four cycles. Maintenance PB was administered until disease progression or unacceptable toxicity. RESULTS:One hundred forty-four Colombian patients with a median follow-up of 13.8 months and a median number of 6 maintenance cycles (range, 1-32) were assessed. The ORR among the patients was 66% (95% CI, 47% to 79%). The median PFS and (OS) rates were 7.9 months (95% CI, 5.9-10.0 months) and 21.4 months (95% CI, 18.3 to 24.4 months), respectively. We documented grade 3/4 hematologic toxicities, including anemia (14%), neutropenia (8%), and thrombocytopenia (16%). The identified grade 3/4 non-hematologic toxicities were proteinuria (2%), venous thrombosis (4%), fatigue (11%), infection (6%), nephrotoxicity (2%), and sensory neuropathy (4%). No grade >3 hemorrhagic events or hypertension cases were reported. OS was significantly higher in patients with the lowest TS mRNA levels [median, 29.6 months (95% CI, 26.2-32.9)] compared with those in patients with higher levels [median, 9.3 months (95% CI, 6.6-12.0); p = 0.0001]. TS expression (mRNA levels or protein expression) did not influence the treatment response. CONCLUSION:Overall, PCB followed by maintenance pemetrexed and bevacizumab was effective and tolerable in Hispanic patients with non-squamous NSCLC. This regimen was associated with acceptable toxicity and prolonged OS, particularly in patients with low TS expression. We found a role for Ki67 and TS expression as prognostic factors. |
url |
http://europepmc.org/articles/PMC4871516?pdf=render |
work_keys_str_mv |
AT andresfelipecardona pemetrexedcarboplatinbevacizumabfollowedbymaintenancepemetrexedbevacizumabinhispanicpatientswithnonsquamousnonsmallcelllungcanceroutcomesaccordingtothymidylatesynthaseexpression AT leonardorojas pemetrexedcarboplatinbevacizumabfollowedbymaintenancepemetrexedbevacizumabinhispanicpatientswithnonsquamousnonsmallcelllungcanceroutcomesaccordingtothymidylatesynthaseexpression AT beatrizwills pemetrexedcarboplatinbevacizumabfollowedbymaintenancepemetrexedbevacizumabinhispanicpatientswithnonsquamousnonsmallcelllungcanceroutcomesaccordingtothymidylatesynthaseexpression AT oscararrieta pemetrexedcarboplatinbevacizumabfollowedbymaintenancepemetrexedbevacizumabinhispanicpatientswithnonsquamousnonsmallcelllungcanceroutcomesaccordingtothymidylatesynthaseexpression AT hernancarranza pemetrexedcarboplatinbevacizumabfollowedbymaintenancepemetrexedbevacizumabinhispanicpatientswithnonsquamousnonsmallcelllungcanceroutcomesaccordingtothymidylatesynthaseexpression AT carlosvargas pemetrexedcarboplatinbevacizumabfollowedbymaintenancepemetrexedbevacizumabinhispanicpatientswithnonsquamousnonsmallcelllungcanceroutcomesaccordingtothymidylatesynthaseexpression AT jorgeotero pemetrexedcarboplatinbevacizumabfollowedbymaintenancepemetrexedbevacizumabinhispanicpatientswithnonsquamousnonsmallcelllungcanceroutcomesaccordingtothymidylatesynthaseexpression AT mauriciocuello pemetrexedcarboplatinbevacizumabfollowedbymaintenancepemetrexedbevacizumabinhispanicpatientswithnonsquamousnonsmallcelllungcanceroutcomesaccordingtothymidylatesynthaseexpression AT luiscorrales pemetrexedcarboplatinbevacizumabfollowedbymaintenancepemetrexedbevacizumabinhispanicpatientswithnonsquamousnonsmallcelllungcanceroutcomesaccordingtothymidylatesynthaseexpression AT claudiomartin pemetrexedcarboplatinbevacizumabfollowedbymaintenancepemetrexedbevacizumabinhispanicpatientswithnonsquamousnonsmallcelllungcanceroutcomesaccordingtothymidylatesynthaseexpression AT carlosortiz pemetrexedcarboplatinbevacizumabfollowedbymaintenancepemetrexedbevacizumabinhispanicpatientswithnonsquamousnonsmallcelllungcanceroutcomesaccordingtothymidylatesynthaseexpression AT sandrafranco pemetrexedcarboplatinbevacizumabfollowedbymaintenancepemetrexedbevacizumabinhispanicpatientswithnonsquamousnonsmallcelllungcanceroutcomesaccordingtothymidylatesynthaseexpression AT rafaelrosell pemetrexedcarboplatinbevacizumabfollowedbymaintenancepemetrexedbevacizumabinhispanicpatientswithnonsquamousnonsmallcelllungcanceroutcomesaccordingtothymidylatesynthaseexpression AT clicap pemetrexedcarboplatinbevacizumabfollowedbymaintenancepemetrexedbevacizumabinhispanicpatientswithnonsquamousnonsmallcelllungcanceroutcomesaccordingtothymidylatesynthaseexpression |
_version_ |
1725895659149590528 |